Hebrew College’ Yissum and Israeli Biotech Clearmind Drugs’s Psychedelic-Derived … | Information

Isranalytica2023, theAnnual assembly of the Israel Analytical Chemical Society, supplied Clearmind with the chance to garner visibility for its drug candidate MEAI from attendees at oneof the most important annual analytical chemistry conferences within theworld

Tel Aviv, Israel / Vancouver, Canada, Jan. 25, 2023 (GLOBE NEWSWIRE) — Clearmind Drugs Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or the “firm”), a biotech firm centered on discovery and growth of novel psychedelic-derived therapeutics to unravel main under-treated well being issues, at this time introduced that Professor Joseph Tam, D.M.D., Ph.D., who led the pre-clinical trial for its drug candidate MEAI for treating weight problems, introduced the newest outcomes at Isranalytica2023.

The presentation, titled “The Psychoactive Drug 5-Methoxy-2-aminoindane (MEAI) Ameliorates Weight problems and its Metabolic Problems,“ included information from not too long ago introduced pre-clinical outcomes demonstrating efficacy of Clearmind’s drug candidate MEAI for treating weight problems and metabolic syndrome.

Isranalytica 2023, the Annual Assembly of the Israel Analytical Chemical Society, ranks as one of many world’s largest annual analytical chemistry conferences. Professor Joseph Tam, D.M.D., Ph.D., heads the Weight problems and Metabolism Laboratory, and he’s an Affiliate Professor of Pharmacology on the Hebrew College’s Institute for Drug Analysis. Together with Dr. Saja Baraghithy, Ph.D., he led the pre-clinical trial as a part of Clearmind’s sturdy collaboration with the Hebrew College and its know-how switch firm  Yissum.

“We’re honored that our analysis companion, Professor Joseph Tam, selected to current the promising outcomes of our MEAI-based remedy for weight problems to professionals and medical friends,” stated Clearmind’s CEO Dr. Adi Zuloff-Shani. “One in all our targets is to develop the attention to our distinctive remedies among the many scientific and medical group, as a large community will facilitate our future scientific applications.”

About Clearmind Drugs Inc.

Clearmind is a psychedelic pharmaceutical biotech firm centered on the invention and growth of novel psychedelic-derived therapeutics to unravel widespread and underserved well being issues, together with alcohol use dysfunction. Its main goal is to analysis and develop psychedelic-based compounds and try and commercialize them as regulated medicines, meals or dietary supplements.

The corporate’s mental portfolio presently consists of seven patent households. The corporate intends to hunt extra patents for its compounds at any time when warranted and can stay opportunistic relating to the acquisition of extra mental property to construct its portfolio.

Shares of Clearmind are listed for buying and selling on Nasdaq and the Canadian Securities Trade beneath the image “CMND” and the Frankfurt Inventory Trade beneath the image “CWY”.

For additional data go to: https://www.clearmindmedicine.com or contact:

Investor Relations

make investments@clearmindmedicine.com

Phone: (604) 260-1566

Normal Inquiries

Data@Clearmindmedicine.com

www.Clearmindmedicine.com

About Yissum

Yissum is the know-how switch firm of The Hebrew College of Jerusalem. Based in 1964, it serves as a bridge between cutting-edge tutorial analysis and a world group of entrepreneurs, buyers, and business. Yissum’s mission is to profit society by changing extraordinary improvements and transformational applied sciences into business options that tackle our most pressing world challenges. Yissum has registered over 11,000 patents globally; licensed over 1,140 applied sciences and has spun out greater than 200 firms. Yissum’s enterprise companions span the globe and embrace firms resembling Boston Scientific, ICL, Intel, Johnson & Johnson, Merck, Novartis and lots of extra. For additional data please go to www.yissum.co.il

FORWARD-LOOKING STATEMENTS:

This press launch comprises “forward-looking statements” inside the that means of the Personal Securities Litigation Reform Act and different securities legal guidelines. Phrases resembling “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and related expressions or variations of such phrases are meant to establish forward-looking statements. For instance, the Firm is utilizing forward-looking statements when it discusses the outcomes of preclinical trials, conducting future trials, the outcomes of future tasks, the submission of patent purposes and that psychedelic primarily based remedies maintain potential to deal with and supply devoted options for varied psychological well being circumstances. Ahead-looking statements are usually not historic details, and are primarily based upon administration’s present expectations, beliefs and projections, a lot of which, by their nature, are inherently unsure. Such expectations, beliefs and projections are expressed in good religion. Nevertheless, there might be no assurance that administration’s expectations, beliefs and projections shall be achieved, and precise outcomes could differ materially from what’s expressed in or indicated by the forward-looking statements. Ahead-looking statements are topic to dangers and uncertainties that might trigger precise efficiency or outcomes to vary materially from these expressed within the forward-looking statements. For a extra detailed description of the dangers and uncertainties affecting the Firm, reference is made to the Firm’s stories filed every now and then with the Securities and Trade Fee (“SEC”), together with, however not restricted to, the dangers detailed within the Firm’s last prospectus (registration No. 333-265900) filed with the SEC on November 16, 2022. Ahead-looking statements converse solely as of the date the statements are made. The Firm assumes no obligation to replace forward-looking statements to replicate precise outcomes, subsequent occasions or circumstances, modifications in assumptions or modifications in different elements affecting forward-looking data besides to the extent required by relevant securities legal guidelines. If the Firm does replace a number of forward-looking statements, no inference ought to be drawn that the Firm will make extra updates with respect thereto or with respect to different forward-looking statements. References and hyperlinks to web sites have been supplied as a comfort, and the knowledge contained on such web sites shouldn’t be integrated by reference into this press launch. Clearmind shouldn’t be liable for the contents of third-party web sites.